A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy.

Trial Profile

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Docetaxel (Primary) ; Bicalutamide; Leuprorelin
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004048)
    • 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top